A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/17 (2006.01) A61P 7/06 (2006.01)
Patent
CA 2598452
Methods of treating anemic disorders in human subjects comprising administering a VEGF antagonist comprising a fusion polypeptide having an immunoglobulin-like (Ig) domain 2 of the VEGF receptor FItI and Ig domain 3 of the VEGF receptor FIkI or Flt4, and a multimerizing component. Further included are methods of preventing anemia, increasing hematocrit levels, and increasing or stimulating erythropoietin, particularly in subjects being treated for cancer with chemotherapeutic agents and/or radiation.
L'invention concerne des méthodes de traitement de troubles anémiques chez des sujets humains, qui comprennent l'administration d'un antagoniste du VEGF. Celui-ci comprend un polypeptide de fusion comportant le domaine 2 du récepteur Flt1 du VEGF du type immunoglobuline (Ig) et le domaine 3 d'Ig du récepteur Flk1 ou Flt4 du VEGF, et un composant multimérisant. L'invention concerne aussi des procédés visant à prévenir l'anémie, à accroître les taux d'hématocrites et à accroître ou à stimuler l'érythropoïétine, en particulier chez des sujets atteints de cancer et qui sont traités par des agents chimiothérapeutiques et/ou par rayonnement.
Cedarbaum Jesse M.
Holash Jocelyn
Rudge John
Stahl Neil
Yancopoulos George D.
Blake Cassels & Graydon Llp
Regeneron Pharmaceuticals Inc.
LandOfFree
Treating anemia by inhibition of vegf does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating anemia by inhibition of vegf, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating anemia by inhibition of vegf will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2045251